Startup profile · funding coverage
OmniSeq funding, valuation and investors
Genomic and immune profiling diagnostics for solid tumors; Roswell Park spinout acquired by Labcorp.
Keep track of OmniSeq
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired · Buffalo, NY
Overview
OmniSeq was a CAP/CLIA molecular diagnostic laboratory founded in 2015 in Buffalo, NY as a commercial spinout from Roswell Park Comprehensive Cancer Center's Center of Personalized Medicine. The company developed genomic and immune profiling assays for solid tumors, including the OmniSeq INSIGHT next-generation sequencing platform used to inform precision oncology treatment and clinical trial matching. After a multi-year distribution partnership with Labcorp, Labcorp announced on July 29, 2021 that it was acquiring OmniSeq to expand its oncology portfolio. OmniSeq's tests and services were integrated into Labcorp Oncology; the independent startup is no longer operating as a standalone company.
Why OmniSeq is interesting
Buffalo precision-oncology lab spun from Roswell Park in 2015 and acquired by Labcorp in July 2021 — a rare Upstate molecular diagnostics exit into a national lab platform.
Product & use cases
Clinical laboratory genomic and immune profiling for solid tumors (NGS and related assays), later offered through Labcorp Oncology after acquisition.
- Oncologists ordering comprehensive solid tumor genomic/immune profiles
- Biopharma biomarker and trial stratification services
- Precision oncology treatment and trial matching
Key facts
- Founded 2015 — Roswell Park Center of Personalized Medicine commercial spinout, Buffalo, NY
- CAP-accredited, CLIA-licensed molecular diagnostic lab for solid tumor genomic/immune profiling
- Jun 2021: Labcorp and OmniSeq launched OmniSeq INSIGHT NGS platform (pre-close partnership product)
- Acquired by Labcorp (Jul 29, 2021) — oncology portfolio expansion
- Standalone website retired; coverage is historical exit profile
Funding history (newest first)
Acquisition
2021-07- Labcorp (lead)
Competitive landscape
Edge: Roswell Park–origin molecular lab with combined genomic and immune profiling — strategic enough for Labcorp to acquire after years of exclusive distribution.
Precision oncology diagnostics consolidated toward large lab and pharma-aligned platforms. OmniSeq's path — Roswell spinout, Labcorp distribution, then Labcorp acquisition — matches that consolidation pattern.
-
Foundation Medicine (Roche) direct
Leading comprehensive genomic profiling incumbent.
-
Guardant / liquid biopsy platforms adjacent
Blood-based profiling; different sample type.
-
Other CAP/CLIA oncology NGS labs direct
Hospital and commercial labs offering tumor panels.
Notable stories
- Labcorp and OmniSeq launched INSIGHT together in June 2021, weeks before Labcorp announced the July 29, 2021 acquisition (Labcorp Oncology / PR Newswire).
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover OmniSeq's financing or category context.
FAQs about OmniSeq
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.